Literature DB >> 12766834

The health and economic burden of genital warts in a set of private health plans in the United States.

Ralph P Insinga1, Erik J Dasbach, Evan R Myers.   

Abstract

We estimated the prevalence of and costs associated with genital warts among privately insured individuals from the perspective of a private health plan in the United States. Health care claims data were derived from a sample of 3,664,686 privately insured individuals. The database was limited to cases of disease for which an insurance claim was generated, with costs reflecting inpatient, outpatient, and pharmacy payments from all sources. We identified 5095 cases of genital warts (1.7 cases per 1000 person-years) billed through the health plans during 2000. The prevalences of and health plan costs associated with genital warts were highest among women aged 20-24 years (6.2 cases and $1692 in costs per 1000 person-years) and men aged 25-29 years (5.0 cases and $1717 in costs per 1000 person-years). On average, individual episodes of care for genital warts involved 3.1 physician visits and incurred costs of $436. These are the first age- and sex-specific estimates of the prevalence and cost of genital warts for a US health plan.

Entities:  

Mesh:

Year:  2003        PMID: 12766834     DOI: 10.1086/375074

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  64 in total

1.  Risk factors for incident condyloma in a multinational cohort of men: the HIM study.

Authors:  Gabriella M Anic; Ji-Hyun Lee; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Mary R Papenfuss; Martha Abrahamsen; Heather Stockwell; Dana E Rollison; Yougui Wu; Anna R Giuliano
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

Authors:  Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Mary E Penny; Carlos Aranda; Eftyhia Vardas; Harald Moi; Heiko Jessen; Richard Hillman; Yen-Hwa Chang; Daron Ferris; Danielle Rouleau; Janine Bryan; J Brooke Marshall; Scott Vuocolo; Eliav Barr; David Radley; Richard M Haupt; Dalya Guris
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

4.  Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.

Authors:  Francesco Saverio Mennini; Gianluca Fabiano; Andrea Marcellusi; Paolo Sciattella; Mario Saia; Silvia Cocchio; Vincenzo Baldo
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

5.  Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study.

Authors:  Gabriella M Anic; Ji-Hyun Lee; Heather Stockwell; Dana E Rollison; Yougui Wu; Mary R Papenfuss; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Martha Abrahamsen; Anna R Giuliano
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

Review 6.  The economic burden of noncervical human papillomavirus disease in the United States.

Authors:  Delphine Hu; Sue Goldie
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

Review 7.  [Polyphenon E. A new topical therapy for condylomata acuminata].

Authors:  G Gross
Journal:  Hautarzt       Date:  2008-01       Impact factor: 0.751

8.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

9.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08

10.  Model for assessing human papillomavirus vaccination strategies.

Authors:  Elamin H Elbasha; Erik J Dasbach; Ralph P Insinga
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.